Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from RBC Capital

RBC Capital analyst Randall Stanicky maintained a Buy rating on Jazz Pharmaceuticals (JAZZResearch Report) on August 6 and set a price target of $184. The company’s shares opened today at $137.32.

According to TipRanks.com, Stanicky is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -18.9% and a 22.6% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals Plc, Amneal Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $177.50, implying a 29.3% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $180 price target.

See today’s analyst top recommended stocks >>

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $85.2 million. In comparison, last year the company had a net profit of $92.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.